Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.

Reich, K; Langley, R G; Lebwohl, M; Szapary, P; Guzzo, C; Yeilding, N; Li, S; Hsu, M-C; Griffiths, C E M

Reich, K; Langley, R G; Lebwohl, M; Szapary, P; Guzzo, C; Yeilding, N; Li, S; Hsu, M-C; Griffiths, C E M.

Affiliation

Reich K; Dermatologikum Hamburg, Hamburg, Germany Dalhousie University, Halifax, NS, Canada.

Br J Dermatol ; 164(4): 862-72, 2011 Apr.

Article in En | MEDLINE | ID: mdl-21332467

Subject(s)

Antibodies, Monoclonal/adverse effects; Immunologic Factors/adverse effects; Myocardial Infarction/chemically induced; Psoriasis/drug therapy; Stroke/chemically induced; Adult; Antibodies, Monoclonal, Humanized; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction/epidemiology; Myocardial Infarction/mortality; Odds Ratio; Psoriasis/complications; Risk Factors; Severity of Illness Index; Stroke/epidemiology; Stroke/mortality; Ustekinumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Stroke / Immunologic Factors / Antibodies, Monoclonal / Myocardial Infarction Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Br J Dermatol Year: 2011 Type: Article Affiliation country: Canada

Fulltext

XML

PubMed Links

Search on Google